Drug Profile
Diazepam - Pfizer
Alternative Names: VanquixLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator King Pharmaceuticals
- Developer Pfizer; University of Chicago
- Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 21 Apr 2015 No recent reports of development identified - Phase-III for Epilepsy (Intermittent therapy) in USA (IM)
- 01 Jul 2014 Pfizer completes a phase III trial in Epilepsy in USA (NCT00319501)
- 08 Mar 2013 Pfizer re-initiates enrolment in a phase III trial for Epilepsy in the USA (NCT00319501)